Stockholm, Sweden; London, UK; and Houston, Texas – 01/09/2026 – Qbtech today announced that Tony Doyle has been appointed Interim Chief Executive Officer, following Carl Reuterskiold's decision to step down as CEO after many years leading the company.
Carl has played a pivotal role in building Qbtech from an early-stage business into the largest global provider of objective ADHD assessment and treatment support solutions. Under his leadership, the company expanded internationally to 16 countries, strengthened its clinical and commercial position, and established itself as a trusted partner to several thousand healthcare providers, clinicians, and more than 1.5 million patients.
Carl will continue to support Qbtech as an advisor and shareholder, helping to ensure a smooth transition and supporting the continued success of the business.
Asa Hedin, Chair of the Board of Directors, said:
"On behalf of the Board, I would like to thank Carl for his exceptional leadership and contribution to Qbtech. He has played a pivotal role in building the company into the trusted and respected business it is today."
"Tony has been a key part of Qbtech's journey for many years and has made a significant contribution to the company's growth and success. His deep knowledge of the business, our customers and our strategy makes him the right leader to provide continuity and momentum as we continue to build on the strong foundations established by Carl."
Carl Reuterskiold said:
"Leading Qbtech has been a privilege and one of the most rewarding experiences of my career. I am incredibly proud of what we have built together, and of the positive impact Qbtech has had on patients, clinicians and healthcare systems. The company has a strong future ahead of it, supported by exceptional people, innovative products and a clear mission. Tony has been a key contributor to our success for many years, and I am confident he is the right person to lead the business in this next chapter."
Tony Doyle, Interim Chief Executive Officer, said:
"I am honoured to take on the role of Interim CEO and grateful for the confidence placed in me by the Board. Carl has made an extraordinary contribution to Qbtech, and I would like to thank him for his leadership, support and partnership over many years."
"Having spent many years helping to build Qbtech, I know first-hand the strength of our people, our products and our purpose. Our mission and strategy remain unchanged and continue to be highly relevant. Together, we will remain focused on supporting healthcare professionals and patients, delivering value to our customers and improving outcomes for people affected by ADHD."
About Qbtech
Qbtech is a world-leading provider of objective ADHD assessment and treatment support solutions. Through its evidence-based technology, Qbtech helps healthcare professionals make more informed clinical decisions and improve outcomes for patients through better assessment, treatment, and follow-up of ADHD.
Media Contact
Richard Hemming
Marketing Director
Qbtech